TY - JOUR T1 - Method development and characterization of the low molecular weight peptidome of human wound fluids JF - medRxiv DO - 10.1101/2020.10.29.20222208 SP - 2020.10.29.20222208 AU - Mariena J.A. van der Plas AU - Jun Cai AU - Jitka Petrlova AU - Karim Saleh AU - Sven Kjellström AU - Artur Schmidtchen Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/03/2020.10.29.20222208.abstract N2 - Wound infections are significant challenges globally, and there is an unmet need for better diagnosis of wound healing status and infection. The wound healing process is characterized by proteolytic events that are the result of basic physiological processes involving coagulation and complement activation, but also dysfunctional activations by endogenous and bacterial proteases. Peptides, downstream reporters of these proteolytic actions, could therefore serve as a promising tool for diagnosis of wound healing and infection. In the present study, we demonstrate a method for the characterisation of the complete peptidome of human wound fluids. We compare acute non-infected wound fluids obtained post-surgery with plasma samples and find significantly higher protein and peptide numbers in wound fluids, which typically were also smaller in size as compared to plasma-derived peptides. Finally, we analyse wound fluids collected from dressings after facial skin graft surgery and compare three uninfected and normally healing surgical wounds with three inflamed and S. aureus infected wounds. The results identify unique peptide patterns of various selected proteins including coagulation and complement factors, as well as proteases and antiproteinases. Together, the work defines a workflow for analysis of peptides derived from human wound fluids and demonstrate a proof-of-concept that such wound fluids can be used for analysis of qualitative differences of peptide patterns derived from wound fluids on larger patient cohorts, providing novel biomarkers for wound healing and infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from Alfred Osterlund Foundation, Edvard Welanders Stiftelse and Finsenstiftelsen (Hudfonden), Lars Hiertas Memorial Foundation, LEO Foundation, O.E. and Edla Johanssons Foundation, the Royal Physiographic Society in Lund, Swedish Research Council (project 2017-02341), the Swedish Government Funds for Clinical Research (ALF) and Ake Wibergs Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was carried out in accordance with the recommendations of the Ethics Committee at Lund University, Lund, Sweden with written informed consent from all subjects in accordance with the Declaration of Helsinki. The protocols for the use of human blood (permit no. 657-2008) and human wound materials (708-01, 509-01, and 762-2013) were approved by the Ethics Committee at Lund University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the manuscript and its supplements. ER -